-
Sector Analysis
Acromegaly and Gigantism - Epidemiology Forecast to 2029
Acromegaly and gigantism are rare disorders of the pituitary gland, characterized by the hypersecretion of growth hormone (GH). In 98% of the cases of acromegaly and gigantism, the hypersecretion of GH results from a benign GH- secreting pituitary adenoma (Sesmilo, 2013). A common sign of acromegaly is enlarged hands and feet, and the disease can also cause gradual changes in the shape of the face, such as a protruding lower jaw and brow, an enlarged nose, thickened lips, and wider...
-
Sector Analysis
Diabetic Retinopathy - Epidemiology Forecast to 2029
Diabetic retinopathy is a sight-threatening microvascular eye complication of type 1 and type 2 diabetes, and is a leading cause of preventable visual disability and blindness in working-age adults throughout the world (Rubino et al., 2007). Only those with diabetes are at risk for diabetic retinopathy. Characteristically asymptomatic, diabetic retinopathy has few recognizable ophthalmic symptoms until the onset of actual visual loss (Fong et al., 2004). The pathophysiology of diabetic retinopathy stems from damage to the microvasculature of the retina...
-
Product Insights
Pompe Disease Disease - Global Clinical Trials Review, H1, 2020
GlobalData's clinical trial report, “Pompe Disease Global Clinical Trials Review, H1, 2020" provides an overview of Pompe Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Pompe Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Diabetic Retinopathy Disease - Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Diabetic Retinopathy Global Clinical Trials Review, H2, 2020" provides an overview of Diabetic Retinopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Retinopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Gestational Diabetes Clinical trials scenario. This report provides top line data relating to the clinical trials on Gestational Diabetes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
-
Product Insights
Pre-Diabetes Impaired Glucose Tolerance Disease - Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Amyloidosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of an abnormal protein called the light chain and its subsequent deposition in the body. It may also occur because of dialysis. Symptoms include fatigue, chest pain, swelling, and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy...
-
Product Insights
Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes. The Diabetic Macular Edema drugs in development market research report provide comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by...
-
Product Insights
Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs, and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet, and cracked skin. The predisposing factors include diabetes, smoking, and kidney diseases. Treatment includes...
-
Product Insights
Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity, and cognitive dysfunction. The Hypoglycemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.